Details

Autor(en) / Beteiligte

• Zafar, Ameeduzzafar
• Alruwaili, Nabil K.
• Imam, Syed Sarim
• Alsaidan, Omar Awad
• Alharbi, Khalid Saad
• Alzarea, Sami I.
• Yasir, Mohd
• Afzal, Muhammad
• Alshehri, Sultan
• Alanazi, Abdullah S.

Titel

Bioactive Luteolin Entrapped Chitosan-PLGA Nanoparticles: Formulation Optimization to In-Vivo Preclinical Evaluation

Ist Teil von

• Journal of cluster science, 2023, Vol.34 (1), p.437-449

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2023

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Diabetes mellitus is an incurable metabolic disease characterized by a change in blood glucose level. Luteolin (LT) is a bioactive flavonoid and reported for potential antidiabetic activity. LT loaded chitosan (CH)—polylactic co-glycolic acid (PLGA) nanoparticles (NPs) were prepared by emulsification—evaporation process and further optimized by Box-Behnken design using CH (A), PLGA (B), and polyvinyl alcohol (C) as formulation variables and their effect evaluated on particle size (Y 1 ), drug loading (Y 2 ), and entrapment efficiency (Y 3 ). CH-PLGA-LT-NPs showed a particle size of 273.43 ± 5.24 nm, DL of 15.25 ± 2.43%, and EE of 65.28 ± 1.76%. The zeta potential was found to be positive with spherical surface morphology. CH-PLGA-LT-NPs exhibited sustained drug release (68.23 ± 6.17%) than LT-dispersion (29.66 ± 4.2%). The permeation study and pharmacokinetic study results revealed 3.19 fold as well as 2.63 fold (AUC 0-t ) enhancement in pure LT. CH-PLGA-LT-NPs also exhibited a significant (P < 0.05) reduction in blood glucose level in streptozotocin-induced diabetic rats than LT-dispersion. CH-PLGA-LT-NPs also showed notable improvement in biochemical parameters as compared to diabetic control and LT-dispersion group. The results concluded that LT-CH-PLGA-NPs is a good alternative to the treatment of diabetes.